Lubell, Y; White, L; Varadan, S; Drake, T; Yeung, S; Cheah, PY; Maude, RJ; Dondorp, A; Day, NP; White, NJ; Parker, M (2014) Ethics, economics, and the use of primaquine to reduce falciparum malaria transmission in asymptomatic populations. PLoS medicine, 11 (8). e1001704. ISSN 1549-1277 DOI: 10.1371/journal.pmed.1001704

Downloaded from: http://researchonline.lshtm.ac.uk/1883938/

DOI: 10.1371/journal.pmed.1001704

Usage Guidelines

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Ethics, Economics, and the Use of Primaquine to Reduce Falciparum Malaria Transmission in Asymptomatic Populations

Yoel Lubell¹,²*, Lisa White¹,², Sheila Varadan³, Tom Drake¹,², Shunmay Yeung⁴, Phaik Yeong Cheah¹,², Richard J. Maude¹,², Arjen Dondorp¹,², Nicholas P. J. Day¹,², Nicholas J. White¹,², Michael Parker⁵

¹ Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand, ² Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, United Kingdom, ³ International Commission of Jurists, Geneva, Switzerland, ⁴ Faculty of Public Health and Policy, The London School of Hygiene & Tropical Medicine, London, United Kingdom, ⁵ The Ethox Centre, Nuffield Department of Population Health, University of Oxford, United Kingdom

Summary Points

- Rapidly achieving falciparum malaria elimination could require mass antimalarial treatment of asymptomatic individuals to eliminate the parasite reservoir that sustains malaria transmission.
- Primaquine is the only licenced antimalarial that kills mature Plasmodium falciparum gametocytes, but it is associated with a dose-dependent risk of haemolysis in G6PD-deficient individuals.
- We discuss ethical and economic considerations pertaining to mass primaquine administration in malaria elimination programmes, which go beyond those encountered in other public health interventions. These include the lower direct benefit for individuals at higher risk, the increasingly available diagnostic tests for G6PD deficiency, and the economic implications of testing.
- We propose a research agenda to assist informed and rational policy decision making in the rollout of primaquine mass drug administration that is pragmatically and economically viable and within acceptable ethical standards.

Mass drug administration (MDA) could, however, be essential to malaria elimination. This is because of the substantial proportion of malaria infections that are asymptomatic and chronic at densities lower than detection thresholds for microscopy or malaria rapid tests, even in areas of low malaria transmission. These infections still produce gametocytes, and in low-endemic settings are estimated to account for 20%–50% of transmission episodes [2–6]. Targeting asexual parasites in these carriers using drugs such as artemisinin combination therapies will limit de-novo gametocyte development but will not kill gametocytes already present. An MDA which includes a gametocytocidal drug might therefore be more effective than...
Unique Challenges in Use of Primaquine as a P. falciparum Gametocytocide in MDA

Previous public health interventions, such as the smallpox and polio eradication campaigns, posed comparable risks to vaccinated individuals, as does the use of sulfadoxine–pyrimethamine and other antimalarials in intermittent preventive treatment often provided to children and pregnant women in malaria-endemic regions [12–14]. The use of primaquine in MDA introduces additional unique challenges in several important respects. In terms of the risks involved, compared with smallpox and eradication campaigns, a failed MDA programme could cause significant harm if it contributed to emerging drug resistance and a resurgence of malaria in populations with lowered immunity.

Ethically, there are two additional aspects that make use of primaquine as a P. falciparum gametocytocide in MDA contentious. Firstly, the use of primaquine offers no curative or prophylactic effect to the individuals receiving it (other than the indirect benefit of reducing the likelihood of future malaria), but it does expose them to risk of harm (albeit substantially less than with higher doses, or with longer courses as used to eliminate P. vivax). Asymptomatic carriers targeted by the programme are less likely to benefit from the programme because of their immunity to malaria.

Secondly, the technology to identify G6PD-deficient individuals and exclude them is from treatment is increasingly available. While intuitively appealing, this involves significant trade-offs – it would lower gametocytocidal treatment coverage, jeopardising the campaign and therefore increasing the probability of a rebound in malaria cases; and it requires significant resources to prevent what is likely to be a very low degree of harm. Assuming a cost of US$2 per test, the above estimated mortality of 1–2 million, and a life expectancy of 20 years, would result in a cost per DALY averted in the range of US$50,000 to US$100,000, far exceeding what is normally considered cost-effective in low-income settings. The substantially lower estimated risk associated with single-dose primaquine would imply an even higher cost per DALY averted. This investment, from a consequentialist perspective, might be unethical, if these resources could be used elsewhere to generate far greater health benefits; but from other ethical perspectives and given the unique context, use of the tests could still be considered an ethical obligation.

Taken together, the decision to implement MDA with primaquine introduces challenges both within public health ethics and between public health ethics and those of clinical practice [15,16].

The Public Health Perspective

At the core of public health ethics is the ambition of improving the health of populations whilst minimising potential risks to the liberty or autonomy of individuals [14]. A simple “back of the envelope” consequentialist assessment suggests that, on average, the risk of malaria mortality in low-transmission settings is at least several hundred-fold that of a fatal adverse event following low-dose primaquine (based on the 2012 World Malaria Report annual malaria mortality rate of 0.02% in endemic areas and an estimated risk of primaquine-induced mortality equal to or lower than 1–2 per million, derived largely from the higher dosages used for the radical cure of vivax malaria [9,10]). It is important to note that for vivax malaria the risk/benefit ratio of primaquine MDA will be very different, as although there may be individual benefit from prevention of relapse, the required primaquine dose and the associated risk is much higher, while the risks associated with vivax malaria are lower, in which case the consequentialist assessment will be far less favourable.

Despite a favourable consequentialist assessment, an unequal distribution of risk amongst different ethnic groups and marginalized communities with poorer access to medical care to manage adverse events poses further challenges. The confluence of malaria transmission, marginalized communities with poorer access to medical care to manage adverse events poses further challenges. The confluence of malaria transmission, marginalized communities with poorer access to medical care to manage adverse events poses further challenges.
The spread of artemisinin-resistant patients to complete their treatment [20].

diseases, such as interning tuberculosis patients to complete their treatment [20].

The Health-Care Provider Perspective

Although health providers administering treatments in an MDA programme might be committed to reducing malaria transmission in the population, their primary concern is likely to be the well-being of individuals in their care. Indeed, health-care professionals have a legal and moral duty to act in the best interests of the patient. In practical terms, this means that health-care professionals exercising their duty of care will generally administer medication only where the risk of harm is minimal or where the individual benefit outweighs the risk of harm [23].

This is prima facie at odds with the administration of a potentially harmful drug to an asymptomatic or even uninfected individual for the benefit of the wider community. Much depends, however, on the degree of risk involved. For therapeutic interventions the obligation to ensure informed consent is proportional to the risk involved [24,25]; in a public health context it could be contended that disclosure requirements should be higher, especially where there is no direct health benefit. Assuming a community engagement programme has adequately informed recipients of the risks and benefits involved, a key question from the provider perspective remains the extent to which consent from the recipient (implicit or explicit) provides sufficient normative justification to administer the intervention. From their perspective consent on behalf of the recipient is necessary but not in itself sufficient to act in accordance with clinical ethics [25], unless they are equally convinced the benefits outweigh the risks. Engagement of health-care providers in the planning and execution of the programmes to ensure their support is therefore imperative.

Even if implicit informed consent is normatively acceptable, ensuring its validity will be challenging. Will individuals comprehend the difference between a public health intervention and an individual curative treatment [26]? Will they find it difficult to object to such treatment, either because they are grateful to, or overly respectful towards, health-care providers? Will peer pressure place undue influence on them, particularly if it is understood that refusal to participate could jeopardise the initiative for which others have accepted the risk? These questions are of particular concern amongst marginalized communities.

**Possible Ways Forward**

Considering these challenges, how best to proceed? One option is to continue minimising the burden of clinical cases without pushing forward with an aggressive elimination campaign. This will spare the resource-intensive phase required in stamping out final infections and avoiding re-importation, as well as potential harm associated with measures such as primaquine MDA. The risk here is that the spread of artemisinin resistance undermines our ability to effectively treat clinical cases coupled with a rebound in transmission, resulting in a large increase in morbidity and mortality. The global impact could be enormous.

With a more ambitious objective of interrupting transmission, an alternative strategy targeting asymptomatic infections and circulating the ethical challenges in MDA is to screen for parasitaemia and treat only positive individuals, offering a clearer benefit to drug recipients. The malaria tests available for wide-scale screening, however, often fail to identify low levels of parasitaemia [27]. As such, a large proportion of asymptomatic carriers – the primary target of this intervention – would be missed, potentially rendering the programme ineffective.

Given these limitations, MDA with single dose primaquine might be the only option for successful elimination campaigns. The risk associated with this low dose is small, even in G6PD-deficient individuals, and while its existence raises ethical questions both in relation to public health and to clinical care, these can be managed with careful consideration. On this basis it is our view that MDA programmes that include the use of primaquine are justifiable, but will require carrying out a significant programme of research together with implementation (see Box 1). A research and implementation agenda for primaquine
MDA will require consideration of overall societal benefit against the obligation to protect individuals and minority groups from harm, as well as developing models of good practice for ensuring effective mechanisms for obtaining valid consent and respecting the duty of care owed to a patient by the health-care professional. These measures should be considered not only an ethical obligation, but a practical necessity to ensure high levels of compliance, key to the programme’s success.

Acknowledgments

We would like to thank Elizabeth Ashley and Lorenz von Sciddein for their very helpful suggestions on the manuscript.

References


Author Contributions

Wrote the first draft of the manuscript: YL MP. Contributed to the writing of the manuscript: YL LJW SRV TD SY PYC RM MD AD NPJD NJW MP. ICMJE criteria for authorship read and met: YL LJW SRV TD SY PYC RM MD AD NPJD NJW MP. Agree with manuscript results and conclusions: YL LJW SRV TD SY PYC RM MD AD NPJD NJW MP.